Cabergolin effect on IVF for endometriosis

Comparison the impact of Cabergolin and a placebo on IVF outcomes after laparoscopic surgery in cases of endometriosis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20091012002576N35

Enrollment

200

Registered

2024-01-17

Start date

2024-01-20

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Female infertility of other origin

Interventions

Intervention 1: Control group: After laparoscopy for endometriosis, placebo (placebo Cabergolin 0.5mg/week, Aboreihan Company) plus dinogest 2.5 mg/daily for 3 months will be prescribed then pregnancy

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Approved endometriosis by pathology Presence good quality embryo

Exclusion criteria

Exclusion criteria: Hypersensitivity to cbergoline BMI>30 Diabetes melitus Hydrosalpinx Severe male factor AMH<1

Design outcomes

Primary

Measure	Time frame
?Chemical pregnancy. Timepoint: Two weeks after embryo transfer. Method of measurement: Blood sample for BhCG.	—

Secondary

Measure	Time frame
Clinical pregnancy. Timepoint: Four weeks after embryo transfer. Method of measurement: Heart beat activity in transvaginal sonogram.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Davari Tanha

Tehran University of Medical Sciences

Fatedavtanha@gmail.com+98 21 8880 0115

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026